Bayer's Monsanto wins appeal in Roundup cancer lawsuit
By Victor Swezey
Bayer said an appeals court ruled in favor of its Monsanto unit in a case alleging the agricultural-chemical maker should have warned users about the cancer risk of its Roundup weedkiller.
The German pharmaceutical giant said Thursday that the Third Circuit Court of Appeals in Philadelphia ruled unanimously that the Federal Insecticide, Fungicide, and Rodenticide Act superseded state laws that formed the basis for the suit.
"The company is pleased with the unanimous decision from the Third Circuit holding that plaintiff's state-based warning claims are expressly preempted by FIFRA," it said. Bayer (XE:BAYN) bought Monsanto for more than $60 billion in 2018, and has faced a raft of lawsuits over the herbicide.
The company said the ruling on the Schaffner v. Monsanto case creates a circuit split among federal appellate courts, making a review by the U.S. Supreme Court necessary.
Bayer added that it stands by the Roundup products and says they aren't carcinogenic.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-15-24 1953ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now